Education
About Us
Working with TipRanks
Follow Us
Biogen (BIIB)
NASDAQ:BIIB
BIIB Stock Chart & Stats
$179.89
-$1.36(-0.89%)
At close: 4:00 PM EST
$179.89
-$1.36(-0.89%)
Day’s Range― - ―
52-Week Range$110.04 - $190.20
Previous CloseN/A
Volume268.56K
Average Volume (3M)1.71M
Market Cap
$26.39B
Enterprise Value$29.12B
Total Cash (Recent Filing)$3.96B
Total Debt (Recent Filing)$6.59B
Price to Earnings (P/E)16.4
Beta0.67
Next Earnings
Feb 06, 2026EPS Estimate
1.63Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)4.81
Shares Outstanding146,702,270
10 Day Avg. Volume1,151,507
30 Day Avg. Volume1,712,166
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)1.33
Price to Sales (P/S)2.30
P/FCF Ratio8.86
Enterprise Value/Market Cap1.10
Enterprise Value/Revenue2.92
Enterprise Value/Gross Profit4.16
Enterprise Value/Ebitda8.33
Forecast
1Y Price Target
$189.05Price Target Upside5.09% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering22
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market Expansion Via Diagnostics And AdherenceAnalyst notes that wider adoption of blood-based biomarker testing combined with more convenient dosing and high patient persistence on Leqembi could expand the treatable Alzheimer's population and support prescription growth.
Pipeline And Rare-disease UpsideAnalyst highlights multiple late-stage programs and promising rare-disease candidates as potential upside catalysts that could materially boost the company's growth profile if trial readouts are positive.
Regulatory Approval For Leqembi FormulationAnalyst expects approval of a subcutaneous induction option for Leqembi would enable treatment initiation outside infusion centers and create a commercial advantage versus intravenous-only competitors.
Bears Say
Commercialization And Uptake ChallengesAnalyst observes logistical hurdles and reimbursement uncertainty that are slowing Leqembi uptake, pointing to a gradual sales ramp and pressure on near-term revenue.
Multiple Sclerosis Franchise Pressure From BiosimilarsAnalyst warns that biosimilar competition is causing meaningful share loss in the multiple sclerosis franchise, reducing core earnings and increasing reliance on new product success.
Pipeline Concentration And Program CutsAnalyst cautions that recent program cost cuts have left the development pipeline underdeveloped and increased dependence on a single Alzheimer's treatment, raising execution and valuation risk.
Biogen News
BIIB FAQ
What was Biogen’s price range in the past 12 months?
Biogen lowest stock price was $110.03 and its highest was $190.20 in the past 12 months.
What is Biogen’s market cap?
Biogen’s market cap is $26.39B.
When is Biogen’s upcoming earnings report date?
Biogen’s upcoming earnings report date is Feb 06, 2026 which is in 5 days.
How were Biogen’s earnings last quarter?
Biogen released its earnings results on Oct 30, 2025. The company reported $4.81 earnings per share for the quarter, beating the consensus estimate of $3.882 by $0.928.
Is Biogen overvalued?
According to Wall Street analysts Biogen’s price is currently Undervalued.
Does Biogen pay dividends?
Biogen does not currently pay dividends.
What is Biogen’s EPS estimate?
Biogen’s EPS estimate is 1.63.
How many shares outstanding does Biogen have?
Biogen has 146,702,270 shares outstanding.
What happened to Biogen’s price movement after its last earnings report?
Biogen reported an EPS of $4.81 in its last earnings report, beating expectations of $3.882. Following the earnings report the stock price went up 1.184%.
Which hedge fund is a major shareholder of Biogen?
Currently, no hedge funds are holding shares in BIIB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biogen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$189.05 (5.09% Upside)
$189.05 (5.09% Upside)
Blogger Sentiment
Bullish
BIIB Sentiment 75%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 725.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days <0.1%
Last 30 Days ▲ 8.9%
Last 30 Days ▲ 8.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
23.01%
12-Months-Change
Fundamentals
Return on Equity
9.31%
Trailing 12-Months
Asset Growth
3.16%
Trailing 12-Months
Company Description
Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
BIIB Company Deck
BIIB Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Biogen's earnings call reflected a strong performance in new product launches and pipeline progress, with significant revenue growth in key segments offsetting some challenges, particularly in Europe and China. The financial results and strategic focus on pipeline expansion suggest a positive outlook.View all BIIB earnings summariesBIIB Revenue Breakdown
74.55% Product revenue
18.09% Revenue from anti-CD20 therapeutic programs
0.62% Alzheimer's collaboration revenue
6.74% Contract manufacturing, royalty and other revenue
BIIB Stock 12 Month Forecast
Average Price Target
$189.05
▲(5.09% Upside)
Technical Analysis
Ownership Overview
0.18% Insiders
30.72% Mutual Funds
0.20% Other Institutional Investors
40.84% Public Companies and Individual Investors